Semiannual Report — FY2026 H1
What Renascience Inc. reported for the period from 2026-04-01 to 2027-03-31.
Filed 2026-11-11View the original on EDINET
How much it says
45Typical
What moved here
15named for the first time
Its own wording
46terms
Which filing this is
16/ 16newest
No officer data yetThis company's filings have not been read for officers yet. Nothing is missing from the filings — the roster simply has not been extracted.
The gist
During the interim accounting period, the Company continued research and development in oncology centered on RS5614, anti-aging and longevity, and AI-enabled software as a medical device, while advancing clinical trials, including completion of dosing in the Phase III CML trial and completion of enrollment in the Phase III malignant melanoma trial. The Company also recognized milestone revenue, but recorded an interim net loss due to business expenses including research and development costs, and offset the deficit through a reduction in capital reserves.
Komori's summary of this document, not the document's own words.45Typical
How much this filing saysA weighted roll-up of 9 rubric dimensions, each scored from a fixed set of questions asked against this filing — built only from the 34 this document could answer. It measures how specific the disclosure is, not whether the company is doing well. Derived from the data, not editorial.
84
Very detailed
31
Thin
0
Almost nothing
75
Very detailed
100
Very detailed
0
Almost nothing
13
Almost nothing
11
Almost nothing
77
Very detailed
R&D spend76百万円Money spent making new things.
Cash left over-2億円Cash from the business, less what went into equipment.
Spent on equipment1百万円Plants, machines — things meant to last.
Employees2Headcount at the end of this period.
How to read this page
This is not the documentIt is Komori's reading of the filing submitted to EDINET. The original is linked above.
The score is not a verdictIt measures how specific the disclosure is. It says nothing about results or where the share price goes.
When it updatesContent lands once the filing has been read through. Right after submission, the summary can still be empty.